This spotlight was recently featured in the American South Asian Network (ASAN). When the IPPF named Ramesh Swamy its new Board...
A Message from our Executive Director Dear IPPF Community, Today, I’m incredibly grateful to share the exciting news that the U.S. FDA...
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal...
Akari Therapeutics recently announced positive results from the Phase II study of investigational nomacopan in bullous pemphigoid (BP) were published online...
The Global Dermatology Coalition, a patient-led, multi-stakeholder group of organizations, has launched during the 75th World Health Assembly in Geneva.
The following Letter to the Editor was published in the Journal of the European Academy of Dermatology and Venereology on April...
Akari Therapeutics recently announced positive results from the Phase II study of investigational nomacopan in bullous pemphigoid (BP) were published online...
The following was published as a Letter to the Editor in the British Journal of Dermatology in November, 2021. The letter...
The IPPF is thrilled to share that Hannah Yale won the 2021 RareVoice award for State Advocacy by a Teenager, which...
The IPPF is grateful to share that we have received a one-time, $50,000 grant from the Chan Zuckerberg Initiative in support...
We're excited to share that last month, the IPPF's Marc Yale was named as President of the Board of Directors of...
The 2021 IPPF Scientific Symposium (September 19-21) featured three days of live sessions and abstract discussions. The event, held in cooperation...
On April 23, 2019, Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
The results of our survey are published in the Journal of The European Academy of Dermatology and Venereology: COVID-19 Pandemic and...
The International Alliance of Dermatology Patient Organizations (also known as GlobalSkin) is inviting pemphigus and pemphigoid patients to participate in a...
The U.S. FDA has granted Fast Track Designation for DSG3-CAART, Cabaletta Bio's lead product candidate for treatment of mucosal pemphigus vulgaris,...
Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B...
23 patients were evaluated for efficacy in an adaptive Phase 2 trial aiming to establish optimal treatment regimen argenx, a clinical-stage...
Genentech, a member of the Roche Group, announced data this week from the Phase III PEMPHIX study evaluating the efficacy and...
Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for the treatment of...